| Background:Bronchial asthma (Bronchial Asthma, following referred to as asthma) is a participation by a variety of cells (such as eosinophils, mast cells, T lymphocytes, neutrophils, etc.) and cellular elements, With reversible airway obstruction and nonspecific airway hyperresponsiveness as characteristics of the chronic airway inflammatory disease. According to the World Health Organization (WHO) statistics, there are around300million asthma patients,and the national prevalence rate ranging from1%to13%. The number of asthmatics in China is more than30million, and the prevalence rate of bronchial asthma is about1%to4%. The course of many patients is for up to ten years to several decades. In recent years, Given the upward trend in asthma morbidity and mortality of many of the world’s countries and regions, bronchial asthma has become the global public health problem and even social problems. Many governments,families and individuals is not bear the social burden and medical cost of bronchial asthma,and therefore the clinical study effective treatment for acute asthma exacerbation is imperative.This article summarizes the related information of the treatment of the60cases with bronchial asthma acute exacerbation of light-moderate patients (TCM is Leng Xiao) from my hospital of Respiratory Medicine outpatient. Evaluate the clinical efficacy and safety that is Pingchuan decoction cure acute exacerbation of asthma patients (TCM is Leng Xiao), from the improvement of clinical symptoms (general TCM symptom score, single TCM symptom score), pulmonary function, safety index and other aspects.Objective:Using the randomized controlled method, Through the observation of the clinical symptoms(including wheezing, cough, sputum, chest tightness, and throat wheezing sound), lung function(including FEV1,FEV1/FVC) and other aspects of all meeting the conditions of the asthma patients in the change before and after the treatment, study the improving situation of the main symptoms of bronchial asthma acute exacerbation of light-moderate patients (TCM is Leng Xiao) and the impact on lung function, systematic reviews the clinical efficacy and security of Pingchuan decoction to treat bronchial asthma acute exacerbation of light-moderate patients (TCM is Leng Xiao).Methods:In strict accordance with the subject design criteria and exclusion criteria to select the60cases with bronchial asthma acute exacerbation of light-moderate patients (TCM is Leng Xiao). Using the randomized controlled clinical trial design, the patients are divided into traditional Chinese medicine group (test group) and western medicine group (control group), according to the1:1design, and30cases in each group. Among them, the average age of the control group is44.57±8.20years, and given the treatment of the doxofylline tablets.The average age of the experimental group is44.37±8.16years, and given the treatment of Pingchuan decoction. The treatmenting time of the two group is7days (one course of treatment).7days later the clinical symptoms (mainly include wheezing, cough, sputum production, chest and throat wheezing sound)(general TCM symptom score, single TCM symptom score), lung function (including FEV1, FEV1/FVC) and the changes of the safety indicators before and after a course of treatment were observed. Statistically, analyse the improving situation of the condition and security in the two groups of patients before and after treatment. Lung function specific steps is in strict accordance with the procedure in our hospital Jaeger spirometer.Results:(1) Clinical comparison:the total effective rate of the clinical efficacy of the test group was93.3%, and the total effective rate of the clinical efficacy of the control group was86.6%. The total effective rate of test group total efficiency was higher than that in the control group. Statistically, through the clinical efficacy comparison of the test group and the control group, the two were no significant difference (P>0.05).(2)TCM syndromes comparison:the total effective rate of TCM syndromes of the test group was93.3%, and the total effective rate of TCM syndromes of the control group was80%. The total effective rate of the test group was higher than that in the control group. Statistically, through the TCM syndromes comparison of the test group and the control group, the two were no significant difference (P>0.05).(3) General TCM symptom score:between the two groups of patients before and after treatment group, there were significant differences (P<0.05), and that was the clinical symptoms of the two groups’patients before and after treatment group was significantly reduced, and the group comparison of the two groups of patients was a significant difference (P<0.05), and the test group was better than the control test. Single TCM symptom score:comparing two groups of patients before and after treatment group showed a significant difference(P<0.05), and the group comparison of the two groups of patients was a significant difference (P<0.05), and the test group was better than the control test.(4) Evaluation of lung function:the improving key Indicators FEV1, FEV1/FVC of the lung function of the two groups’ patients showed no significant difference (P>0.05). comparing two groups of patients before and after treatment group showed a significant difference(P<0.05),Compared the FEV1, FEV1/FVC improvement of the two groups’patients before and after treatment group showed a significant difference (P<0.05).(5) Monitoring of adverse reactions:the blood, electrocardiogram, and liver and kidney function of the two groups were no obvious abnormalities. In the control group one patient appeared the slight palpitations and other adverse reactions after taking medicine, and relieved by rest. The test group showed no adverse reactions.Conclusions:(1)The control group and the test group, given the appropriate treatment in accordance with the subject design, achieved good results in terms of clinical efficacy, TCM syndromes and the improving lung function. Although the experimental group did not significantly superior to the control group, the test group in improving General TCM symptom score, single TCM symptom score and other aspects was better than the control group. The results showed that the treatment of bronchial asthma acute exacerbation of light-moderate patients(TCM is Leng Xiao) by Pingchuan decoction have better clinical efficacy than the control group, and the improvement of the main symptoms of bronchial asthma (including wheezing, cough, sputum, chest and throat wheezing sound) compared to western medicine has certain advantages.(2) none of the two groups of patients appear the obvious abnormal blood and electrocardiogram. Although there was one case of adverse reactions in the control group, as a whole, the two groups in the treatment of bronchial asthma have the good clinical safety. In summary, it can confirm that Pingchuan decoction treatment of bronchial asthma acute exacerbation of light-moderate patients (TCM is Leng Xiao) has better clinical efficacy and safety, and Pingchuan decoction can be applied in clinical practice. |
PDF Full Text Request